Pfizer Inc to Review Oral GLP-1 Data Call Transcript
Good day, everyone, and welcome to Pfizer's Analyst and Investor Call to review oral GLP-1 data presented at the European Association for the Study of Diabetes 2022. Today's call is being recorded.
At this time, I would like to turn the call over to Mr. Ronen Tamir, Vice President, Investor Relations. Please go ahead, sir.
Thank you very much, and thank you all for joining us today. We're very happy to be presenting some exciting GLP-1 clinical data to you all.
Today, we will be making forward-looking statements that are subject to substantial risks and uncertainties. And I'd just like to remind you that these forward-looking statements speak only as of the webcast's original date, and we undertake no obligation to update or revise them in the future. You can find additional information on forward-looking statements in our SEC filing, including Forms 10-Q and 10-K, under the section labeled Risk Factors and Forward-looking Information and factors that may affect future results.
Now allow me to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
